On May 21, the U.S. Court of Appeals for the District of Columbia Circuit upheld the right of pharmaceutical manufacturers to place at least some restrictions on the shipment of 340B drugs to contract pharmacies of 340B covered entities. The decision, in Novartis Pharmaceuticals Corporation v. Johnson, echoed a similar decision by another appeals court in January 2023 in Sanofi Aventis U.S. LLC v. United States Department of Health and Human Services….
By: Manatt, Phelps & Phillips, LLP
By: Manatt, Phelps & Phillips, LLP